Novem Group’s Pacific Biosciences PACB Stock Holding History

Novem Group’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,000	Closed	-$18.7K	–	470
2025 Q4	$18.7K	Buy	+10,000	New	+$19.2K	﹤0.01%	417

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Novem Group's PACB Position: Q1 2026 in Review

Novem Group sold out of Pacific Biosciences (PACB) in Q1 2026, closing a stake of 1,100 shares — an estimated $2.06K sold.

Novem Group first reported a position in PACB in Q4 2025 and held it in 1 quarter. The position peaked at $2.06K in Q4 2025. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Novem Group reported no remaining Pacific Biosciences position as of Q1 2026 after selling out during the quarter.
Novem Group sold 1,100 Pacific Biosciences shares in Q1 2026, an estimated $2.06K.
Novem Group first reported a position in Pacific Biosciences in Q4 2025 and held it in 1 quarter.
Novem Group's Pacific Biosciences position peaked at $2.06K in Q4 2025.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Novem Group's 13F filing for Q1 2026, filed 13 Apr 2026.